Nuclear export of macromolecules is often deregulated in cancer cells. Tumor suppressor proteins, such as p53, can be rendered inactive due to aberrant cellular localization disrupting their mechanism of action. The survival of chronic lymphocytic leukaemia (CLL) cells, among other cancer cells, is assisted by the deregulation of nuclear to cytoplasmic shuttling, at least in part through deregulation of the transport receptor XPO1 and the constitutive activation of PI3K-mediated signaling pathways. It is essential to understand the role of individual proteins in the context of their intracellular location to gain a deeper understanding of the role of such proteins in the pathobiology of the disease. Furthermore, identifying processes that underlie cell stimulation and the mechanism of action of specific pharmacological inhibitors, in the context of subcellular protein trafficking, will provide a more comprehensive understanding of the mechanism of action. The protocol described here enables the optimization and subsequent efficient generation of nuclear and cytoplasmic fractions from primary chronic lymphocytic leukemia cells. These fractions can be used to determine changes in protein trafficking between the nuclear and cytoplasmic fractions upon cell stimulation and drug treatment. The data can be quantified and presented in parallel with immunofluorescent images, thus providing robust and quantifiable data.
Introduction
The transportation of macromolecules between the nucleus and cytoplasm has long been established to play a key role in normal cellular function and is often deregulated in cancer cells 1, 2 . Such deregulation can result from overexpression/mutation of proteins that control nuclear export. One such protein Exportin-1 (XPO1), is a transport receptor that exports >200 nuclear export signal (NES)-containing proteins into the cytoplasm from the nucleus 2 . XPO1-cargos include p53, FOXO family members and IB, contributing to their inactivation by inhibiting their mechanism of action 1, 2, 3 . Further protein mislocalization can occur when microenvironmental signals impinge upon the cancer cells, leading to the activation of intracellular signaling pathways such as the phosphatidyl-inositol-3-kinase (PI3K)/Akt pathway, resulting in inactivation of FOXO family members and subsequent export from the nucleus 4, 5 . Such mislocalization of tumor suppressor proteins has been implicated in the progression of a number of hematological and solid tumors 1, 2, 6 . The development of small molecule inhibitors for clinical use in hematological malignancies (acute myeloid leukemia (AML)/CLL), which bind to and selectively inhibit XPO1 function, underlines the importance of developing appropriate techniques to address the impact of pharmacological agents on the shuttling of proteins between the nuclear and cytoplasmic compartments 6, 7, 8 . Imaging techniques have advanced significantly enabling the identification of proteins in subcellular compartments upon external stimulation of drug treatments, however, the importance of robust and supportive parallel techniques is critical to reliably inform a scientific audience of the validity of a result.
Resting lymphocytes and malignant CLL-B cells isolated from patient blood samples represent a challenge in the generation of nuclear and cytoplasmic fractions due to the high nuclear: cytoplasmic ratio. The optimization of experimental conditions to generate robust and reliable experimental data is of course critical in order to plan future experimental programs. The method described here enables quantification of proteins in the nuclear and cytoplasmic fractions and determines how these proteins can be impacted by cellular stimulation and/or drug treatment.
Isolation of CLL Cells from Patient Blood Samples

Peripheral blood samples from previously consented CLL patients are received from the clinic in EDTA blood collection tubes, accompanied by the white cell count (WCC). Purify the peripheral blood CLL samples according to the WCC. For WCC < 40 x 10
4. After the incubation, add 2 mL of FACS buffer to all the tubes and centrifuge at 300 x g for 5 min at RT to wash the cells. Discard the supernatant and resuspend the bead/cell pellets by gently flicking the tubes. 5. Resuspend tubes 1 -5 in 100 µL of FACS buffer and place on ice until ready to analyze on the flow cytometer. 6. Dilute the DAPI solution to 0.05-0.2 µg/mL in FACS buffer immediately prior to use. The optimal concentration may vary, and titration is recommended. 7. Resuspend tubes 6 and 7 with 100 µL of diluted DAPI solution and incubate the tubes on ice for a minimum of 5 min to allow the cells to stain. NOTE: No further washing is necessary as DAPI must be present in the buffer for dead cells to remain labelled. Once DAPI has been added, cells must be analyzed on the flow cytometer within 4 h. 8. Analyze cells using a flow cytometer.
Preparation of Subcellular Fractions from CLL Cells
NOTE:
When planning the experimental set-up, include a well of unstimulated/untreated cells from which the whole cell extract can be generated.
1. Perform the desired stimulation and/or drug treatment of the MEC1 CLL cell line or isolated primary CLL cells using 10 -20 x 10 6 cells/ condition. Cells will then be used for subcellular fractionation (steps 3.4 & 3.5) or to generate whole cell extract (step 3.6). 2. Preparation of solutions/tubes: Prepare all solutions/buffers freshly on the day of the fractionation, before the cells are harvested. Store the solutions on ice until required and use within 4 h of preparation. 1. PBS/phosphatase inhibitor solution: Prepare the phosphatase inhibitors in PBS by diluting the phosphatase inhibitors 1:20 in 1x PBS (i.e., 0.5 mL of phosphatase inhibitors in 9.5 mL of 1x PBS). NOTE: Ensure the phosphatase inhibitors have not precipitated. If a precipitate is present, heat to 50 °C for 10 min. To determine the optimal concentration of detergent to use for a specific cell type to isolate nuclear and cytoplasmic fractions, perform a detergent gradient initially. A range of 1:20 to 1:60 (i.e., 2.5 μL to 0.8 μL of detergent into 50 μL of Hypotonic Buffer) should be adequate. NOTE: If the volume of hypotonic buffer in step 3.4 is adjusted, ensure the appropriate detergent ratio is maintained. 2. Verify cell lysis by observing cells using a phase contrast microscope before and after addition of detergent. Whole cells appear larger with a dense, dark nucleus. The cytoplasm will appear as a bright halo around the nucleus. NOTE: Appropriate lysis is further confirmed by using Western blotting to analyze specific proteins within the lysed fractions generated from the detergent gradient.
2. Once lysed, centrifuge the samples at 14,000 x g for 30 s at 4 °C. 3. Carefully transfer the supernatant into a pre-chilled, labelled microfuge tube. This cytoplasmic fraction can be stored at -80 °C until required for further analysis. The remaining pellet contains the nuclear fraction (step 3.5). NOTE: Avoid repeated freeze/thaw cycles of the samples. 
Preparation of nuclear fractions:
Downstream Analysis of Subcellular Fractions
NOTE: In this protocol, analysis of the generated cell fractions was carried out by Western blotting using standard protocols, loading equal cell numbers/lane (equivalent to ~10 µg of protein) for nuclear and cytoplasmic fractions. 
Quantification of protein trafficking between nuclear and cytoplasmic fractions:
Representative Results
When planning experiments on primary CLL cells, if assays require a large number of cells (>50 x 10 6 cells), there is a preference to use freshly isolated CLL cells, rather than cryopreserved cells that require thawing, however this is not always possible. This is because the freeze/thaw process can result in the death of up to 50% of the CLL cells, although this is sample dependent. Enrichment of CLL cells with a WCC >40 x 10 6 / mL using density centrifugation as described here (steps 1.3 -1.5) enables a high cell recovery with high purity (≥ 95%) of primary CLL cells. In the sample shown, the WCC = 177 x 10 6 /mL: from a 30 mL blood sample 5 x 10 9 cells were recovered, which represents a cell yield of 94% of total cells. Analysis of this sample by flow cytometry revealed a purity of CLL cells of >95% as indicated by the dual surface expression of CLL cell markers CD19 and CD5 after gating on FSC/SSC, single cells that were DAPI negative (viable cells) (Figure 1) .
Optimization of the subcellular fractionation procedure was carried out using a range of detergent ratios (1:20 to 1:60) during the preparation of the cytoplasmic fraction (step 3.4). Thereafter, the nuclear fractions and WCLs were prepared (steps 3.5 and 3.6 respectively). Immunoblots were performed on the resultant fractions of the CLL cell line MEC1 (Figure 2A) and primary CLL cells (Figure 2B) . The blots were probed for the fraction markers Lamin A/C (nuclear; 74/63 kDa) and β-tubulin (cytoplasmic; 55 kDa) to confirm successful cell fractionation. The fractionation indicates that the optimal detergent level for MEC1 cells is a 1:60 dilution (Figure 2A) , compared with a 1:30 dilution being optimal for primary CLL cells (Figure 2B) , as indicated by an enrichment of nuclear protein and a lack of cytoplasmic protein in the fractions and vice versa. WCLs represent the total protein and act as a positive control for antibodies used to probe the subcellular fractions. It is important to choose appropriate proteins as fraction markers: Figure 2C shows immunoblots of nuclear/cytoplasmic fractions prepared from MEC1 cells in which RNA polymerase II (Rpb1 CTD; 250 kDa) and Lamin A/C were blotted as markers of nuclear fractions, while β-tubulin and γ-tubulin (50 kDa) were used as cytoplasmic markers. It is clear that γ-tubulin is enriched in the cytoplasm however expression is evident in the nucleus, as shown previously 9 .
Once experimental conditions are optimized, an experiment can be performed. In the examples shown, the subcellular localization of FOXO1 in nuclear and cytoplasmic fractions was determined upon stimulation of cells with the B cell antigen receptor (BCR) in the presence or absence of the dual mTORC1/2 inhibitor AZD8055, in MEC1 cells ( Figure 3A) and primary CLL cells (Figure 3B ) 5, 10 .
In both examples, the generation of highly enriched nuclear and cytoplasmic fractions was achieved as indicated by the almost exclusive expression of Lamin in the nuclear fraction and β-tubulin in the cytoplasmic fractions. In both cell types, FOXO1 expression was reduced in the cytoplasm following treatment with AZD8055 compared to NDC, accompanied by an increase of FOXO1 expression in the nuclear compartment, thus demonstrating protein translocation (Figure 3) . To remove the subjectivity of data interpretation, individual immunoblots from five primary CLL samples were quantified within subcellular fractions (step 4; Figure 4A ), using the respective nuclear or cytoplasmic proteins as internal loading controls for each sample, and then normalizing each fraction to the unstimulated (US) no drug control (NDC) control, as indicated. The resultant graph shows trends of FOXO1 movement between the nuclear and cytoplasmic fractions, with AZD8055 reducing the levels of FOXO1 expression in the cytoplasm, while concurrently increasing expression in the nucleus. Furthermore, an elevation in cytoplasmic FOXO1 expression is evident upon BCR crosslinking. 
Discussion
The protocol described provides a fast and efficient method for the generation of nuclear and cytoplasmic fractions from primary CLL cells, and subsequent quantification of protein trafficking between the nuclear and cytoplasmic fractions upon cell stimulation and drug treatment. The data presented demonstrates the ability to detect trafficking of specific proteins, for example, FOXO1, between the nuclear and cytoplasmic fractions, upon treatment with a dual mTOR inhibitor AZD8055 in the presence/absence of BCR crosslinking through F(ab') 2 fragment stimulation (Figure 3 and Figure 4 ). Coupling these experiments with quantification of Western blots from individual CLL patient samples, enables objective analyses of the data generated and demonstrates the robustness of the assay described to quantify global changes in protein localization in CLL cells isolated from patient cohorts (Figure 4) . It is clear from the data that an average of five patient samples in the cytoplasmic fractions reached near significance. Given the clinical heterogeneity of CLL patients 11 , these analyses would ordinarily be carried out on bigger patient cohorts, and/or focused on specific prognostic subgroups of patients to gain a fuller understanding of the cellular response of CLL cells to specific drug treatments.
The data presented demonstrate the importance of choosing protein markers that exclusively reside in either the cytoplasmic or nuclear fractions, as the purity of the fractionation will be confirmed by these markers. β-tubulin was chosen for cytoplasmic fraction confirmation, and Lamin A/C as a nuclear marker. Additional proteins commonly used are GAPDH and α-tubulin to identify the cytoplasmic fraction or Brg1 (SMARCA4), TFIID and RNA Polymerase II for nuclear fraction purity 4, 5 . However, care must be taken when choosing proteins that are highly enriched in specific fractions, and not present in both fractions (e.g., γ-tubulin) (Figure 2C ) 9 . Indeed, GAPDH and actin while generally considered to be cytoplasmic proteins can localize to the nucleus 12, 13 , highlighting the importance of choosing a fraction marker that does not relocate when stimulation or treatment is applied to the cells. Furthermore, it is important to confirm that the protein marker chosen is expressed in the cell of interest by running the WCL alongside the subcellular fractionations.
In the representative experiment shown, the same number of CLL cells was used for each condition (stimulation/drug treatment), and thereafter the fractionation samples were prepared immediately. Loading 10 µg of fractionated protein/lane provides sufficient material for detection of the proteins of interest. As these samples only underwent a short-term drug treatment and stimulation (up to 4 h), it was assumed that the protein level would remain the same in each sample, and a protein assay was not performed. However, if cell treatments are extended (18 -72 h), the level of cell death or proliferation in cells may significantly alter the quality and quantity of protein extracted, dependent on the drug/cell stimulation applied, thus altering protein levels in the treated/stimulated samples. In these cases for longer term drug treatments, it is advisable to carry out protein quantification using a Bradford assay or equivalent, prior to Western blotting to ensure the same amount of protein is run in each lane of the immunoblot. The presence of detergents may interfere with specific protein assays 14 , this interference can be reduced by diluting cell fraction protein samples. In addition, use the complete lysis buffer as the blank, using the same dilution as in the samples being tested.
To provide supporting evidence for findings described here, parallel experiments could be performed using fluorescence microscopy to analyze the location of FOXO1 within CLL cells to enable visualization of these findings 5 . Furthermore, the subcellular fractions generated can also be used for enzyme activity assays or proteomics analysis in further downstream analyses.
Disclosures
The authors have nothing to disclose.
